- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04740892
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
February 2, 2024 updated by: Johnson & Johnson Consumer Inc. (J&JCI)
A Clinical Evaluation of the Safety and Efficacy of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception) of the investigational cream when used in conjunction with a baby wash in babies, toddlers, and children with mild to moderate atopic dermatitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gabrielle Kosmoski
- Phone Number: (908) 874 -1771
- Email: gkosmosk@its.jnj.com
Study Locations
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Dermatology Consulting Services, PLLC
-
-
Virginia
-
Lynchburg, Virginia, United States, 24591
- The Education & Research Foundation, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 6 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
For Child
- Fitzpatrick skin type I to VI
- Child must have at least 1 target lesion based on the atopic dermatitis severity index (ADSI) with a score of 2-12 and an erythema sub score of at least 2 (moderate)
- Has mild to moderate atopic dermatitis (as per Rajka-Langeland Severity Index; graded as 3.0 to 7.5 inclusive)
- Child must have parent-assessed history of itch
- Has parent-perceived sensitive skin For Parents
- Willing to undergo a 3-day washout period prior to the baseline assessments. During this run-in period, parents will be asked to refrain from using prescription and over-the-counter (OTC) eczema treatments on their child; Acute rescue treatment will be permitted (type of rescue treatment will be determined by principal investigator [PI])
- Has signed the informed consent document (ICD), including Health Insurance Portability and Accountability Act (HIPAA) disclosure
Exclusion Criteria:
- Has known allergies or adverse reactions to common topical skincare products or ingredients of the investigational products (IPs)
- Has a history of a confirmed or suspected coronavirus disease 2019 (COVID-19) infection within 30 days prior to Visit 1 For Child
- Presents with a skin condition that may influence the outcome of the study (specifically psoriasis or active skin cancer)
- Severe atopic dermatitis (AD) as determined by the Rajka-Langeland Severity Index For Parent
- Is self-reported to be pregnant or planning to become pregnant during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Wash and Cream Investigational Product (IP)
Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
|
Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Eczema Area Severity Index (EASI) After 4 Weeks of Product Use
Time Frame: Baseline, Week 4
|
EASI is a composite scoring system index which is used to measure the severity of 4 clinical manifestations of atopic dermatitis (erythema, edema/induration/papulation, excoriations, and lichenification) according to the percentage of affected area in each of the 4 body regions (head/neck, trunk, upper limbs, and lower limbs).
Final scores range from 0 (no disease anywhere on the body) to 72 (severest disease on all body areas).
|
Baseline, Week 4
|
Change From Baseline in Atopic Dermatitis Severity Index (ADSI) After 4 Weeks of Product Use
Time Frame: Baseline, Week 4
|
ADSI is a scoring system that reflects the severity of a target eczema lesion.
The ADSI score is a sum of scores for 5 different parameters - erythema, itching, exudation, excoriation, lichenification - which are each measured on a scale of 0 (none) to 3 (severe).
The total score can range from 0 (no eczema signs) to 15 (severe eczema lesion).
|
Baseline, Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Skin Microbiome
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
Change from baseline in skin microbiome in lesion versus adjacent non-lesional site will be assessed.
Microbiome samples collected from the identified lesional site and an adjacent non-lesional site by swabbing technique will be analyzed by using 16s ribonucleic acid (RNA) sequencing.
|
Baseline, Day 1, 3, 7 and Week 4
|
Change From Baseline in EASI
Time Frame: Baseline, Day 1, 3 and 7
|
EASI is a composite scoring system index which is used to measure the severity of 4 clinical manifestations of atopic dermatitis (erythema, edema/induration/papulation, excoriations, and lichenification) according to the percentage of affected area in each of the 4 body regions (head/neck, trunk, upper limbs, and lower limbs).
Final scores range from 0 (no disease anywhere on the body) to 72 (severest disease on all body areas).
|
Baseline, Day 1, 3 and 7
|
Change From Baseline in ADSI
Time Frame: Baseline, Day 1, 3 and 7
|
ADSI is a scoring system that reflects the severity of a target eczema lesion.
The ADSI score is a sum of scores for 5 different parameters - erythema, itching, exudation, excoriation, lichenification - which are each measured on a scale of 0 (none) to 3 (severe).
The total score can range from 0 (no eczema signs) to 15 (severe eczema lesion).
|
Baseline, Day 1, 3 and 7
|
Change From Baseline in Caregiver Itch Assessment Score
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
Parent participant will assess how much itching/scratching the child participant has been exhibiting on a scale of 1 (none) to 4 (all the time).
An option of "I don't have an opinion" will be included.
|
Baseline, Day 1, 3, 7 and Week 4
|
Change From Baseline in Infant Dermatitis Quality of Life Index (IDQoL)
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
IDQoL is a validated questionnaire completed by parents to assess the impact of atopic dermatitis on the quality of life in infants aged 0-3 years.
The Infant's Dermatitis Quality of Life Index is calculated by summing the score of each question: for question 1 (0 [none] to 3 [all the time]), For question 2 (0 [happy] to 3 [always crying]), For question 3 (0 [0-15 minutes to 3 [More than 2 hours]), For question 4 (0 [less than one hour] to 3 [Five hours or more]), and For questions 5 to 10 (0 [None] to 3 [Very much]), resulting in a maximum score of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
The severity of eczema is scored separately and can be correlated with the Infants' Dermatitis Quality of Life Index.
The score of Dermatitis severity ranges from 0 (None) to 4 (Extremely severe).
|
Baseline, Day 1, 3, 7 and Week 4
|
Change From Baseline in Brief Infant Sleep Questionnaire-Revised (BISQ-R) Scale Score
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
BISQ-R is an age-based, norm-referenced scoring system that provides a comprehensive assessment of infant and toddler sleep patterns.
Five (5) items related to sleep onset latency, number, and duration of night wakings, longest stretch of sleep and total night sleep.
Parent perception consists of 3 items related to bedtime difficulty, overnight sleep, and overall child sleep problems.
Parent behaviors consisting of 11 items related to bedtime routine consistency, bedtime, parental behavior at time of sleep onset and night wakings, sleep locations at time of sleep onset and following night wakings that may impact sleep outcomes.
Score ranging from 0-100 is derived for each sub-scale, with higher scores denoting better sleep quality, more positive perceptions of sleep quality, and parental habits that promote healthy sleep behaviors and independent infant sleep, respectively.
Total score is calculated as an average of infant sleep, parent perceptions and parent behavior subscale scores.
|
Baseline, Day 1, 3, 7 and Week 4
|
Parent Perceived Product Efficacy as Assessed by Parental Questionnaire
Time Frame: Baseline (immediately after first use) and Week 4
|
Parent perceived product efficacy will be assessed by using parental questionnaire.
Participant responses for each question will have 5 response options, the following numerical assignment could be one of the following choices: (1) Strongly Disagree, (2) Disagree Somewhat, (3) Neither Disagree or Agree, (4) Agree Somewhat, (5) Strongly Agree.
|
Baseline (immediately after first use) and Week 4
|
Change From Baseline in Transepidermal Water Loss (TEWL) Measurement in Lesion and Adjacent Non-lesional Site
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
Change from Baseline in TEWL measurement on both the identified lesional site and an adjacent or non-lesional site will be reported.
The DermaLab TEWL instrument uses a non-invasive probe, which measures the passive transfer of water through the stratum corneum.
|
Baseline, Day 1, 3, 7 and Week 4
|
TEWL Measurement Difference Between Lesion and Adjacent Non-lesional Site
Time Frame: Day 1, 3, 7 and Week 4
|
TEWL measurement difference between lesional site and an adjacent non-lesional site will be reported.
The DermaLab TEWL instrument uses a non-invasive probe, which measures the passive transfer of water through the stratum corneum.
|
Day 1, 3, 7 and Week 4
|
Change from Baseline in Skin Hydration in Lesion and Adjacent Non-lesional Site
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
Change from Baseline in skin hydration on both the identified lesional site and an adjacent or non-lesional site will be reported.
The DermaLab hydration instrument uses a non-invasive probe, which measures the water content of the stratum corneum.
|
Baseline, Day 1, 3, 7 and Week 4
|
Skin Hydration Difference between Lesion and Adjacent Non-lesional Site
Time Frame: Day 1, 3, 7 and Week 4
|
Skin hydration difference between lesion and adjacent non-lesional site will be reported.
The DermaLab hydration instrument uses a non-invasive probe, which measures the water content of the stratum corneum.
|
Day 1, 3, 7 and Week 4
|
Change From Baseline in Skin pH in Lesion Versus Adjacent Non-lesional Site
Time Frame: Baseline, Day 1, 3, 7 and Week 4
|
Change from Baseline in skin pH on both the identified lesional site and an adjacent or non-lesional site will be reported.
The DermaLab skin pH instrument uses a non-invasive probe, which measures the pH of the stratum corneum.
|
Baseline, Day 1, 3, 7 and Week 4
|
Skin pH Difference between Lesion and Adjacent Non-lesional Site
Time Frame: Day 1, 3, 7 and Week 4
|
Skin pH difference between lesion and adjacent non-lesional site will be reported.
The DermaLab skin pH instrument uses a non-invasive probe, which measures the pH of the stratum corneum.
|
Day 1, 3, 7 and Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zoe Diana Draelos, MD, Dermatology Consulting Services, PLLC
- Principal Investigator: Laura M Brooks, M.D., The Education & Research Foundation, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-4. doi: 10.2340/000155551441314.
- Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.
- Lipozencic J, Wolf R. Atopic dermatitis: an update and review of the literature. Dermatol Clin. 2007 Oct;25(4):605-12, x. doi: 10.1016/j.det.2007.06.009.
- Basra MK, Gada V, Ungaro S, Finlay AY, Salek SM. Infants' Dermatitis Quality of Life Index: a decade of experience of validation and clinical application. Br J Dermatol. 2013 Oct;169(4):760-8. doi: 10.1111/bjd.12563.
- National Psoriasis Foundation, "Topical Steriods Potency Chart," 18 December 2020, [Online]. Available: http;//www.psoriasis.org/potency_chart/.
- Avi Sadeh, D. Sc., Jodi A. Mindell, Ph.D., and Liat Tikotzky, Ph.D. Brief Infant Sleep Questionnaire - Revised Long Form, version January 2020
- Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD; NISC Comparative Sequence Program; Murray PR, Turner ML, Segre JA. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012 May;22(5):850-9. doi: 10.1101/gr.131029.111. Epub 2012 Feb 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 21, 2021
Primary Completion (Actual)
February 6, 2023
Study Completion (Actual)
February 6, 2023
Study Registration Dates
First Submitted
January 21, 2021
First Submitted That Met QC Criteria
February 4, 2021
First Posted (Actual)
February 5, 2021
Study Record Updates
Last Update Posted (Estimated)
February 6, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCSSKB003103 (Other Identifier: Johnson & Johnson Consumer Inc. (J&JCI))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Johnson & Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health.
Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatitis, Atopic
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands
-
AbbVieActive, not recruiting
Clinical Trials on Wash IP
-
University Tunis El ManarCompleted
-
Vedic Lifesciences Pvt. Ltd.Completed
-
TBF Genie TissulaireNot yet recruiting
-
Immunophotonics, Inc.RecruitingSoft Tissue Sarcoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Colon CancerFrance, United Kingdom, United States, Germany, Switzerland
-
TBF Genie TissulaireNot yet recruiting
-
Vedic Lifesciences Pvt. Ltd.Completed
-
National University of SingaporeCompletedSelf Efficacy | Emotion Regulation | Collaborative SkillsSingapore
-
Democritus University of ThraceCompleted
-
University of ArizonaTerminated
-
Techfields IncTerminatedCOVID-19 PneumoniaUnited States, South Africa